Literature DB >> 23513061

Sensitivity and specificity of short-duration transient visual evoked potentials (SD-tVEP) in discriminating normal from glaucomatous eyes.

Cinthi Pillai1, Robert Ritch, Peter Derr, Alberto Gonzalez, Laurie Kopko Cox, John Siegfried, Jeffrey M Liebmann, Celso Tello.   

Abstract

PURPOSE: To evaluate the ability of the short-duration transient visual evoked potential (SD-tVEP) to discriminate between healthy eyes and eyes with early to advanced glaucomatous visual field loss.
METHODS: We tested 30 eyes of 30 healthy controls and 45 eyes of 35 glaucoma patients. Normal eyes had 20/30 or better visual acuity and normal 24-2 Swedish interactive thresholding algorithm (SITA) Standard visual fields. Glaucoma was staged as mild (mean deviation, MD > -6.0 dB), moderate (MD between -6.0 and -12.0 dB), and severe (MD < -12.0 dB). There were 15 eyes in each group. SD-tVEPs were recorded using the Diopsys NOVA-LX System. Each eye was stimulated with a low (Lc) and a high (Hc) Michelson contrast checkerboard pattern. Each test resulted in an Lc and an Hc SD-tVEP response. Each response was evaluated for overall waveform quality, P100 latency, and P100 amplitude referenced to the N75. The sensitivity, specificity, negative predictor value (NPV), and positive predictor value (PPV) were calculated.
RESULTS: Lc latency showed the highest accuracy for discrimination using receiver operating characteristic curves for high and low contrast parameters. The analysis for all subjects resulted in a 91.1% sensitivity, 93.3% specificity, 95.3% PPV, and an 87.5% NPV. Evaluating the mean Lc latency of the mild, moderate, and severe glaucoma patients against controls showed discrimination consistent with the glaucoma severity.
CONCLUSIONS: Short-duration transient VEP objectively identified decreased visual function and discriminated between healthy and glaucomatous eyes, and also showed good differentiation between healthy eyes and those with early visual field loss. VEP may be useful for early diagnosis of glaucoma.

Entities:  

Mesh:

Year:  2013        PMID: 23513061     DOI: 10.1167/iovs.12-10097

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Modelling the risk of visual field loss arising from long-term exposure to the antiepileptic drug vigabatrin: a cross-sectional approach.

Authors:  John M Wild; David L Fone; Saleh Aljarudi; Charlotte Lawthom; Philip E M Smith; Robert G Newcombe; Gareth D Lewis
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

2.  Short-duration transient visual evoked potentials and color reflectivity discretization analysis in glaucoma patients and suspects.

Authors:  Michael Waisbourd; Rebekah H Gensure; Ardalan Aminlari; Sonya B Shah; Nitasha Khanna; Neil Sood; Jeanne Molineaux; Alberto Gonzalez; Jonathan S Myers; L Jay Katz
Journal:  Int J Ophthalmol       Date:  2017-02-18       Impact factor: 1.779

3.  Preferential Loss of Contrast Decrement Responses in Human Glaucoma.

Authors:  Anthony M Norcia; Alexandra Yakovleva; Naz Jehangir; Jeffrey L Goldberg
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-10-03       Impact factor: 4.925

4.  Visual evoked potential repeatability using the Diopsys NOVA LX fixed protocol in normal older adults.

Authors:  Richard C Trevino; Carolyn E Majcher; Adreain M Henry; Melinda Rodriguez; William E Sponsel
Journal:  Clin Ophthalmol       Date:  2018-09-07

5.  Association of Diopsys® Short-duration Transient Visual Evoked Potential Latency with Visual Field Progression in Chronic Glaucoma.

Authors:  Richard Trevino; William E Sponsel; Carolyn E Majcher; Joey Allen; Jeffery Rabin
Journal:  J Curr Glaucoma Pract       Date:  2018-03-01

6.  Pattern Electroretinography and Visual Evoked Potentials Provide Clinical Evidence of CNS Modulation of High- and Low-Contrast VEP Latency in Glaucoma.

Authors:  William E Sponsel; Susan L Johnson; Rick Trevino; Alberto Gonzalez; Sylvia L Groth; Carolyn Majcher; Diane C Fulton; Matthew A Reilly
Journal:  Transl Vis Sci Technol       Date:  2017-11-08       Impact factor: 3.283

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.